PML-RARa


Acute Promyelocytic Leukemia (APL) accounts for 10-15% of Acute Myeloid Leukemia (AML) and is one of the most curable forms of leukemia with good sensitivity to all-trans retinoic acid (ATRA). Nearly all APL cases are characterized by the presence of the PML-RARa t(15;17) fusion gene transcript which is required for ATRA treatment response. Researchers have identified the utility of measuring PML-RARa transcripts to aid in the classification of APL, predicting treatment response, and monitoring minimal residual disease (MRD).

 


CytoGenes offers primer mixes, standards, and controls allowing laboratories to detect the three most common PML-RARa fusions by quantitative PCR (bcr1, bcr2, and bcr3). PML-RARa transcripts levels can be normalized against the transcript levels of the endogenously expressed Abl gene.

 

 

References

 

  

Additional Product Information

 
    • Cull EH, Altman JK. Contemporary Treatment of APL. Current hematologic malignancy reports. 2014;9(2):193-201. doi:10.1007/s11899-014-0205-6.
    • Lo-Coco F, Cicconi L. History of Acute Promyelocytic Leukemia: A Tale of Endless Revolution. Mediterranean Journal of Hematology and Infectious Diseases. 2011;3(1):e2011067. doi:10.4084/MJHID.2011.067.

 

PML-RARa Primer Mixes Product Data Sheet

PML-RARa Controls Product Data Sheet

PML-RARa Standards Product Data sheet

PML-RARa Suggested Protocol